Page 177 - 2024-bfw-MyersAP4e-TE

ARTICLE ANALYSIS QUESTION

INSTRUCTIONS: Answer the following question using the source provided. Your response to the
question should be provided in six distinct parts: A, B, C, D, E, and F. Use appropriate psychological
Answers to Unit 1 Article terminology in your response.
Analysis Question 2. Using the source provided, respond to the following questions:
(A) Identify the research method used in the study.
2. (B) State one way the dependent variable was operationally defined.
(C) Describe the meaning of statistical significance in the context of this study.
(A) 1 point The researchers conducted (D) Identify at least one ethical guideline applied by the researchers.
an experiment. (E) Explain the extent to which the research findings may or may not be generalizable using
specific and relevant evidence from the study.
(B) 1 point One operational definition (F) Explain how at least one of the research findings supports or refutes the claim that
of the dependent variable, MDD, is the LY2216684 is effective in treating MDD.
Hamilton Depression Rating Scale.
Source:
(C) 1 point The difference between
the group who took the drug and the Introduction
Distributed by Bedford, Freeman & Worth Publishers. Not for redistribution.
placebo group was not statistically signif- A new norepinephrine reuptake inhibitor LY2216684 is being developed to treat major depressive
icant for the Hamilton Depression Rating disorder (MDD). LY2216684’s efficacy and safety will be compared to a placebo in patients with
Scale. This means the difference might be MDD. Escitalopram, a selective serotonin reuptake inhibitor (SSRI), was used as a comparison.
Participants
due to chance.
Four hundred and sixty-nine adults who resided in India, Mexico, Romania, and the United
(D) 1 point Institutional review boards States and who were outpatients diagnosed with MDD as defined by the Diagnostic and Statistical
Manual of Mental Disorders-Fourth Edition-Text Revision (DSM-IV-TR) participated in this study.
approved the study. Method
(E) 1 point The results of this study are Institutional review boards approved the study, and participants consented to the study in writing.
likely to be generalizable because the Participants were randomly assigned to receive LY2216684, escitalopram, or a placebo pill for
eight weeks, and patients and research staff were unaware of which treatment participants were
researchers had a large sample size from assigned to. Participants completed the clinician-administered Hamilton Depression Rating Scale
a variety of countries. and the Self-Rated Quick Inventory of Depressive Symptomatology to measure the extent to
which these substances impact the experience of MDD.
(F) 2 points The results of this study do Results and Discussion
not support the claim that LY2216684 is The group who took LY2216684 did not show statistically significant reduction in depressive
effective in treating MDD because the symptoms compared to the placebo group when measured by the Hamilton Depression Rating
Scale. However, both the group who took LY2216684 and the group who took escitalopram
group taking that drug did not show Copyright © Bedford, Freeman & Worth Publishers.
showed statistically significant reduction in depressive symptoms as measured by the Self-Rated
a statistically significant reduction in Quick Inventory of Depressive Symptomatology.
depressive symptoms compared to the Information from: Dubé, S., Dellva, M. A., Jones, M., Kielbasa, W., Padich, R., Saha, A., & Rao, P. (2010). A study
of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression.
placebo group when measured by the Journal of Psychiatric Research, 44(6), 356–263. https://www.doi.org/10.1016/j.jpsychires.2009.09.013
Hamilton Depression Rating Scale.

D-4 Appendix D Evidence-Based Questions and Article Analysis Questions

12_myersAPpsychology4e_28116_App-D_D-1_D-18.indd 4 12/02/24 9:19 AM

D-4 Appendix D Evidence-Based Questions and Article Analysis Questions

12_HammerTE4e_47547_App-D_D-1_D-18_2pp.indd 4 12/02/24 9:21 AM